Symbol="AGIO"
AssetType="Common Stock"
Name="Agios Pharm"
Description="Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The company is headquartered in Cambridge, Massachusetts."
CIK="1439222"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="88 SIDNEY STREET, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="1474003000"
EBITDA="-370639008"
PERatio="None"
PEGRatio="0"
BookValue="18.66"
DividendPerShare="0"
DividendYield="0"
EPS="-3.78"
RevenuePerShareTTM="0.346"
ProfitMargin="0"
OperatingMarginTTM="-19.9"
ReturnOnAssetsTTM="-0.19"
ReturnOnEquityTTM="-0.194"
RevenueTTM="19017000"
GrossProfitTTM="12536000"
DilutedEPSTTM="-3.78"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="5.74"
AnalystTargetPrice="39.8"
TrailingPE="-"
ForwardPE="2.466"
PriceToSalesRatioTTM="164.39"
PriceToBookRatio="1.623"
EVToRevenue="107.31"
EVToEBITDA="-2.763"
Beta="0.962"
num_52WeekHigh="34.76"
num_52WeekLow="21.07"
num_50DayMovingAverage="26.7"
num_200DayMovingAverage="26.53"
SharesOutstanding="55581000"
DividendDate="None"
ExDividendDate="None"
symbol="AGIO"
open="26.40"
high="26.40"
low="25.65"
price="25.98"
volume="386015.00"
latest_trading_day="2023-08-02"
previous_close="26.79"
change="-0.81"
change_percent="-3.0235%"
aroon_positive_momentum_days="50"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="50"
Volume_recent_avg="464641"
Change_recent_avg="0.02"
Delta_recent_avg="0.94"
Variance_recent_avg="0.47"
Change_ratio_recent_avg="0.05"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="50"
Aroon_momentum_negative="50"
image_negative_thumbnail_id_1="140"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0036.jpeg"
image_negative_thumbnail_id_2="96"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0080.jpeg"
image_neutral_thumbnail_id_1="570"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0029.jpeg"
image_neutral_thumbnail_id_2="561"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0038.jpeg"
image_positive_thumbnail_id_1="976"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0138.jpeg"
image_positive_thumbnail_id_2="651"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0057.jpeg"
image_professor_thumbnail_id_1="1181"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0015.jpeg"
image_professor_thumbnail_id_2="1167"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0001.jpeg"
